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its real prevalence is difficult to estimate since ALP le -
vels are not routinely measured in all children, espe-
cially in those who are asymptomatic6,7. Studies ad-
dressing gender distribution are contradictory: some
have shown that BTHI affects both sexes equally1,5,8,
while others have reported a male predominance2. 
The diagnosis is confirmed by the spontaneous re-
turn of ALP to normal levels within weeks or months
of initial observation. It has no adverse long-term con-
sequences.
BTHI was first described by Bach in 19549, and since
then, some case reports and few case series have been
published in the literature. It remains a relatively un-
recognized condition and it might be a potential, yet
avoidable, concern for physicians when faced with a
marked elevation of ALP levels.
cAse report 
A 4-year-old girl with a 1-year history of persistent
oligoarticular Juvenile Idiopathic Arthritis (JIA) pre-
sented to our Pediatric Rheumatology department for
a routine follow-up visit. She was in clinical remission
for at least 6 months, following two single intra-articular
corticosteroid injections of both knees. She was not ta -
king any medication.
At the time of visit, she was asymptomatic and her
physical examination was unremarkable. Laboratory
tests showed a normal blood count, an erythrocyte sed-
imentation rate of 19 mm/h and a C-reactive protein of
0.1 mg/dL. However, alkaline phosphatase was
markedly increased (1578 U/L; normal age-related val-
ue 150-380 U/L). Alanine-aminotransferase (ALT), as-
partate-aminotransferase (AST), gamma-glutamyl
transpeptidase (GGT) and total bilirubin were within
normal reference ranges, as well as renal function, cal-
cium and phosphorus levels.
Her parents were healthy and reported no com-
plaints or abnormalities in their routine laboratory tests. 
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AbstrAct
Benign transient hyperphosphatasemia of infancy and
early childhood is a self-limiting condition characte -
rized by transiently increased serum alkaline phos-
phatase in the absence of liver, kidney or metabolic
bone diseases. It is often accidentally found in children
under five years old and it might be associated with a
variety of underlying clinical disorders. Its pathophys-
iology remains unclear.
Herein, we report a case of a 4-year-old girl with a
1-year history of persistent oligoarticular Juvenile Id-
iopathic Arthritis, who was found to have transient hy-
perphosphatasemia during a periodic check-up. This
clinical case underlines the importance of promptly rec-
ognizing this benign condition, which avoids unnec-
essary extensive investigations. 
Keywords: Hyperphosphatasemia; Juvenile idiopa thic
arthritis.
IntroductIon
Benign transient hyperphosphatasemia of infancy and
early childhood (BTHI) is a self-limiting condition cha -
racterized by a sudden and temporary increase of serum
alkaline phosphatase (ALP) in the absence of liver, kid-
ney or metabolic bone diseases1,2. It predominantly af-
fects children, especially those aged less than 5 years,
though it has also been reported in adults3-5. 
BTHI is often accidentally detected when laborato-
ry tests are required in healthy children or in children
diagnosed with a variety of unrelated disorders. It can
be found in 1.5% up to 5.1% of the infants, although
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Since there were no other findings suggestive of li -
ver, kidney or metabolic bone disease either in physi-
cal examination or in the laboratory tests, BTHI was
suspected and a “wait-and-see” strategy was adopted.
After two months, there was a spontaneous reduction
of ALP to normal levels (201 U/L), while all the other
laboratory tests remained normal, supporting the di-
agnosis of BTHI.
dIscussIon
ALP is a glycoprotein that can be synthetised through-
out the body in a variety of isoenzymes, depending
upon the site of origin. In humans, there are four isoen-
zymes: tissue-nonspecific (liver, bone, kidney), in-
testinal, placental and germ cell ALP3,10,11. In the pedi-
atric population, under physiological conditions, the
bone and liver fractions contribute 85% and 15% to
the total serum ALP pool, respectively11.
Serum ALP level varies according to age. It is ge -
nerally higher in children than in adults, particularly
during the rapid growth phases of infancy and puber-
ty, due to increased rates of osteoblastic activity11.
In this report, we describe a transient increase in
ALP levels in an asymptomatic 4-year-old child. The
serum level of ALP was increased four to five times
above the upper reference limit for age, which is typi-
cally seen in BTHI, although elevations up to 20 times
the upper standard value have been described12.
In 1985, Kraut et al. proposed the following diag-
nostic criteria for BTHI13: 1) age less than 5 years; 2)
variable clinical picture, ranging from asymptomatic to
variable unrelated symptoms; 3) no evidence of bone
or liver disease on physical examination; 4) no bio-
chemical or laboratory evidence of bone or liver dis-
ease, except for the severe isolated rise in serum ALP;
5) elevation in both bone and liver fractions of ALP; 6)
return to normal ALP values within four months. In
our clinical case, all these diagnostic criteria were met,
except for the identification of ALP isoenzymes, whose
analysis was not performed. However, some studies
have shown that the characteristic isoenzyme pattern
is not always observed in infants with otherwise typi-
cal features of BTHI1,2,14. This could be explained by
differences in laboratory methods, lack of experience
in interpreting results or by a late performance of the
test during the course of the condition when the isoen-
zyme pattern has returned to normality1. Therefore,
failure to meet the fifth criterion described by Kraut
should not preclude the establishment of the diagno-
sis.
Kraut’s criteria have been further contested because,
as previously stated, BTHI has been observed in older
children and adults3-5 and its duration can exceed the
time limit of four months in nearly 20% of cases5,15. In
our clinical case, ALP levels returned to normal after
two months, portraying the classic natural history of
BTHI.
The pathophysiology of BTHI remains poorly un-
derstood. The most plausible explanation for the rise
in ALP levels is a delayed clearance of ALP from circu-
lation due to excessive sialylation13,16. Still, the cause of
this abnormal sialylation is also unclear. Viral infec-
tions (cytomegalovirus, herpes virus, adenovirus, Ep-
stein-Barr virus, rotavirus, enterovirus, among others)
have been suggested as potential triggering factors1,2,14.
In fact, several studies have found a temporal associa-
tion between the development of BTHI and a previous
or concomitant viral infection, especially in the upper
respiratory or gastrointestinal tracts. In our patient, no
history of any recent infection was described.
Although most children are healthy, BTHI has been
linked with a variety of underlying clinical conditions,
such as gastrointestinal diseases (Celiac disease,
Crohn’s disease1,2, multiple congenital anomalies1,
phenylketonuria1, hemophilia1, congenital HIV infec-
tion17, malignancies (leukemia, lymphoma, rhab-
domyosarcoma)18, post liver and kidney transplant19,20
or seizure disorders13. Our patient had a history of
oligoarticular JIA, with 1-year evolution. In the litera-
ture, this association with JIA is rare but has already
been described. In 1985, Jerry Jacobs reported the oc-
currence of BTHI in two girls with polyarticular JIA21.
In these cases, the elevation of ALP occurred 2 and 16
months after the onset of JIA. Nonetheless, we hy-
pothesize that this apparent association may be a tem-
poral coincidence rather than a causal relationship, re-
flecting more frequent monitoring of JIA patients.
The differential diagnosis of increased ALP in child-
hood should include bone disorders (such as rickets,
healing fractures, juvenile Paget’s disease, fibrous dys-
plasia of bone, bone tumors), hepatic disorders
(cholestasis, malignancy) and kidney disorders (chron-
ic renal failure, tubulopathies)22,23. However, these dis-
eases are usually accompanied by other clinical ele-
ments or laboratory abnormalities. Our patient was
totally asymptomatic and there was no other evidence
of hepatic or bone disease in the physical examination
or in the laboratory tests. 
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Drugs such as cotrimoxazole, cyclosporin A, anti-
convulsants and chemotherapy can also cause an in-
crease in ALP13,14,16 but, as mentioned, our patient was
on no medication.
Benign familial hyperphosphatasemia (BFH) also
needs to be considered in the differential diagnosis.
BFH is an inherited disease characterized by the pres-
ence of persistently elevated levels of serum ALP in the
absence of other cause of hyperphosphatasemia24,25.
BFH was excluded in our clinical case by the sponta-
neous reduction of ALP to normal levels and by the fact
that the child’s parents are healthy, with no history of
hyperphosphatasemia. 
In conclusion, the incidental finding of isolated hy-
perphosphatasemia in children should raise the possi-
bility of BTHI. A careful clinical history, physical ex-
amination and routine laboratory tests are usually
sufficient to rule out other possible causative illnesses.
Given the benign nature and self-limiting evolution of
this condition, monitoring of ALP levels is recom-
mended before any further diagnostic steps are under-
taken. The occurrence of BTHI in JIA patients is rare
and it may be found by chance.
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